Special Issue

Toward the Establishment of Personalized Medicine in Psychiatry

Message from the Guest Editors

The current diagnostic criteria used in the field of psychiatry are manipulative and not based on the pathology of the disease. Thus, treatment strategies based on diagnosis may not always lead to the best results. There is currently no clear indicator of the criteria for selecting medication or other treatment options and, therefore, we are required to repeat the steps of trial and error to find the optimal treatment. In this Special Issue of the Journal of Personalized Medicine, we invite researchers in the field to submit original research including (but not limited to) studies on neurophysiology, neuroimaging, the quantification of serum/plasma concentrations of medications and other biological markers. We believe that by consolidating these findings we will be able to develop strategies for individualized treatment in the field of psychiatry.

Guest Editors

Dr. Naoya Oribe

Division of Clinical Research, National Hospital Organization, Hizen Psychiatric Medical Center, 842-0192 Saga, Japan

Dr. Takefumi Ueno

Division of Clinical Research, National Hospital Organization, Hizen Psychiatric Medical Center, 842-0192 Saga, Japan

Deadline for manuscript submissions

closed (10 April 2022)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/82032

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

